Position in ARGX
as of Jun 30, 2026
· filed Jul 20, 2026
Position Value
$338,636
-$37,442 QoQ
Shares Held
365
-29.1% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#344
of 504 holders
Holding Since
Mar 2020
11 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ARGX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Sowell Financial Services LLC holds $6,370,982 across 18 Biotechnology names. ARGX ranks #7 (5.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,930 | $1,455,418 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
|
10,871 | $850,873 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
2,239 | $539,531 | |
| 4 | LGND |
Ligand Pharmaceuticals Inc
|
1,547 | $488,991 | |
| 5 | RPRX |
Royalty Pharma plc
|
7,456 | $418,057 | |
| 6 | RXRX |
Recursion Pharmaceuticals, Inc.
|
110,430 | $405,278 | |
| 7 | ARGX |
Argenx SE
This page
|
365 | $338,636 | |
| 8 | REGN |
Regeneron Pharmaceuticals, Inc.
|
502 | $313,017 |
All Filings in ARGX
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $338,636 | 365 | Shares | Sole | 2026-07-20 | |
| 2026-03-31 | $376,078 | 515 | Shares | Sole | 2026-04-20 | |
| 2025-12-31 | $403,656 | 480 | Shares | Sole | 2026-01-21 | |
| 2025-09-30 | $399,757 | 542 | Shares | Sole | 2025-10-17 | |
| 2025-06-30 | $310,336 | 563 | Shares | Sole | 2025-07-14 | |
| 2025-03-31 | $332,036 | 561 | Shares | Sole | 2025-04-17 | |
| 2021-03-31 | $26,162 | 95 | Shares | Sole | 2021-05-07 | |
| 2020-12-31 | $4,999 | 17 | Shares | Sole | 2021-01-13 | |
| 2020-09-30 | $4,462 | 17 | Shares | Sole | 2020-11-12 | |
| 2020-06-30 | $3,828 | 17 | Shares | Sole | 2020-08-13 | |
| 2020-03-31 | $2,239 | 17 | Shares | Sole | 2020-05-12 | |
| No filing history on record for this holder in this stock. | ||||||